Versions Compared
Key
- This line was added.
- This line was removed.
- Formatting was changed.
Results:
Discussion:
| Expand | ||
|---|---|---|
|
Background:
Testing Gantenerumab bindig to beta amyloid oligomers in the context of the B-Cell receptor. Repeat of experiment done during iGEM.
...
|
| Expand | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||
|
| Expand | ||
|---|---|---|
| ||
Testing Gantenerumab binding to beta amyloid oligomers in the context of the B-Cell Receptor. Repeat of experiment done during iGEM. |
| Expand | ||
|---|---|---|
| ||
Testing beta amyloid binding to cells expressing the components of the B-Cell Receptor. To do this, we are going to treat cells with a saturating concentration of biotin-conjugated beta amyloid. Subsequently, we are going to treat with AlexaFluor 594 conjugated streptavidin. If beta-amyloid binds to the receptor, streptavidin can bind biotin and be detected via flow cytometry. We are controlling for eBFP bleed through into the red channel, background beta-amyloid binding and background streptavidin binding. |
| Expand | ||
|---|---|---|
| ||
hEF1a:eBFP hEF1a:GMabH hEF1a:GmabL hEF1a:CD79A hEF1a:CD79B |